10.13 References

Agence Canadienne des Médicaments et des Technologies de la Santé. (2006). Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd Edition.

Benmahrnia, T., Dionne, P., Tchouaket, E., Fansi, A., & Brousselle, A., I. (2017). Investing in a healthy lifestyle strategy: is it worth it? International Journal of Public Health, 62, 2-13. https://doi.org/10.1007/s00038-016-0884-y

Bohmholdt, A. (2014). Evaluating the Triple Bottom Line Using Sustainable Return on Investment: The Triple Bottom Line Using Sustainable ROI. Remediation Journal, 24, 53–64. https://doi.org/10.1002/rem.21404

Brousselle, A., Benmarhnia, T., & Benhadj, L. (2016). What are the benefits and risks of using return on investment to defend public health programs? Preventive Medicine Reports, 3, 135-138. https://doi.org/10.1016/j.pmedr.2015.11.015

Brousselle, A., Lachaine, J., & Contandriopoulos, A. P. (2011c). L’évaluation économique. In A. Brousselle, F. Champagne, A. P. Contandriopoulos, & Z. Hartz (Eds.), L’Évaluation: Concepts et Méthodes (pp. 187-223). Les Presses de l’Université de Montréal.

Brousselle, A., & Lessard, C. (2011). Economic evaluation to inform health care decision-making: Promise, pitfalls and a proposal for an alternative path. Social Sciences & Medicine, 72(6), 832-839. https://doi.org/10.1016/j.socscimed.2011.01.008

Bryan, S., Coyle, D., Krahn, M., & C, M. (2017). Guidelines for the Economic Evaluation of Health Technologies: Canada. https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition

Caro, J. (2009). Editorial: Pursuing efficiency: A dead end for HTA? Value in Health, 12, S49. https://doi.org/10.1111/j.1524-4733.2009.00559.x

Coast, J. (2004). Is economic evaluation in touch with society’s health values? BMJ, 329(7476), 1233-1236. https://doi.org/10.1136/bmj.329.7476.1233

Domenighetti, G. (1998). Equité, priorités sanitaires et société civile. Epistula ALASS, 26, 9-13.

Donaldson, C., Currie, G., & Mitton, C. (2002). Cost effectiveness analysis in health care: Contraindications. BMJ, 325(7369), 891-894. https://doi.org/10.1136/bmj.325.7369.891

Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (1998). Méthodes d’évaluation économique des programmes de santé, 2e édition. Economica.

Eddama, O., & Coast, J. (2008). A systematic review of the use of economic evaluation in local decision-making. Health Policy, 86, 129-141. https://doi.org/10.1016/j.healthpol.2007.11.010

Fox-Rushby, J., & Cairns, J. E. (2005). Economic evaluation. Maidenhead (NY) Open University Press.

Gold, M., Siegel, J., Russell, L., & Weinstein, M. E. (1996). Cost-effectiveness in health and medicine. Oxford University Press.

Hadorn, D. C. (1991). Setting health care priorities in Oregon. JAMA, 265(17), 2218-2225. https://doi.org/10.1001/jama.1991.03460170072036

Hadorn, D. C. (1996). The Oregon priority-setting exercise: cost-effectiveness and the rule of rescue, revisited. Medical Decision Making, 16(2), 117-119. https://doi.org/10.1177/0272989X9601600203

Kim, Y., Kim, Y., Lee, H. J., Lee, S., S.Y., P., Oh, S. H., Jang, S., T., L., Ahn, J., & Shin, S. (2022). The Primary Process and Key Concepts of Economic Evaluation in Healthcare. Journal of Preventive Medicine and Public Health, 55(5), 415-423. https://doi.org/10.3961/jpmph.22.195

Mauskopf, J. A., Paul, J. E., Grant, D. M., & Stergachis, A. (1998). The role of cost-consequence analysis in healthcare decision-making. PharmacoEconomics, 13(3), 277-288. https://doi.org/10.2165/00019053-199813030-00002

McKie, J., & Richardson, J. (2003). The rule of rescue. Social Science & Medicine, 56(12), 2407-2419. https://doi.org/10.1016/S0277-9536(02)00244-7

National Center for Environmental Economics. (2023). Supplementary Material for the Regulatory Impact Analysis for the Final Rulemaking, “Standards of Performance for New, Reconstructed, and Modified Sources and Emissions Guidelines for Existing Sources: Oil and Natural Gas Sector Climate Review”. EPA Report on the Social Cost of Greenhouse Gases: Estimates Incorporating Recent Scientific Advances. https://www.epa.gov/system/files/documents/2023-12/epa_scghg_2023_report_final.pdf

Nord, E., Pinto, J. L., Richardson, J., Menzel, P., & Ubel, P. (1999). Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Economics, 8(1), 25-39. https://doi.org/10.1002/(SICI)1099-1050(199902)8:1<25::AID-HEC398>3.0.CO;2-H

Pinkerton, S. D., Johnson-Masotti, A. P., Derse, A., & Layde, P. M. (2002). Ethical issues in cost-effectiveness analysis. Evaluation and Program Planning, 25(1), 71-83. https://doi.org/10.1016/S0149-7189(01)00050-7

Rabarison, K. M., Bish, C., Massoudi, M., & Giles, W. (2015). Economic Evaluation Enhances Public Health Decision Making. Frontiers in Public Health, 24(3). https://doi.org/10.3389/fpubh.2015.00164

Rozworski, M. (2014). Methods of economic evaluation: What are the ethical implications for healthy public policy? N. C. C. f. H. P. P. https://www.ncchpp.ca/docs/2014_EvalEcon_Methodes_En.pdf.

Simoens, S., & Laekeman, G. (2005). Applying health technology assessment to pharmaceutical care: Pitfalls and future directions. Pharmacy World & Science, 27(2), 73-75. https://doi.org/10.1007/s11096-004-4098-7

Tchouaket, E., Brousselle, A., Fansi, A., Dionne, P.-A., Bertrand, E., & Fortin, C. (2013). The economic value of Quebec’s water fluoridation program. Journal of Public Health, 21(6), 523-533. https://doi.org/10.1007/s10389-013-0578-3

Tengs, T. O., Meyer, G., Siegel, J. E., Pliskin, J. S., Graham, J. D., & Weinstein, M. C. (1996). Oregon’s Medicaid ranking and cost-effectiveness: Is there any relationship? Medical Decision Making, 16, 99-197. https://doi.org/10.1177/0272989X9601600201

Ubel, P., Loewenstein, G., Scanlon, D., & Kamlet, M. (1996). Individual utilities are inconsistent with rationing choices: A partial explanation of why Oregon’s cost-effectiveness list failed. Medical Decision Making, 16(2), 108-116. https://doi.org/10.1177/0272989X9601600202

Veatch, R. M. (1995). The role of ethics in quality and accountability initiatives. Medical Care, 33, JS69-JS76.

Weinstein, M. C. (2006). Recent developments in decision-analytic modelling for economic evaluation. PharmacoEconomics, 24, 1043-1053. https://doi.org/10.2165/00019053-200624110-00002

Williams, A. (1992). Cost-effectiveness analysis: Is it ethical? Journal of Medical Ethics, 18(1), 7-11. https://doi.org/10.1136/jme.18.1.7

Williams, A. H., & Cookson, R. A. (2006). Equity-efficiency trade-offs in health technology assessment. International Journal of Technology Assessment in Health Care, 22(1), 1-9. https://doi.org/10.1017/S026646230605077X

Williams, I., McIver, S., Moore, D., & Bryan, S. (2008). The use of economic evaluations in NHS decision-making: A review and empirical investigation. Health Technology Assessment, 12(7), iii, ix-x, 1-175. https://doi.org/10.3310/hta12070